Advancing therapy in people with suboptimally controlled basal insulin‐treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries

Aims This subanalysis of the SoliMix trial assessed the efficacy and safety of advancing basal insulin (BI) therapy with iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D) living in Latin American (LATAM) countries, i.e. Argentina and Mexico (N = 160). Materials and Methods SoliMix (Eudr...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2023-09, Vol.25 (9), p.2526-2534
Main Authors: Frechtel, Gustavo, Sauque‐Reyna, Leobardo, Choza‐Romero, Ricardo, Anguiano, Luis, Melas‐Melt, Lydie, Sañudo‐Maury, María Elena
Format: Article
Language:English
Subjects:
Adult
basal insulin
Blood Glucose
Body weight
Body weight gain
Confidence intervals
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Drug Combinations
GLP‐1 receptor agonist
Glycated Hemoglobin
Hemoglobin
Humans
Hypoglycemia
Hypoglycemia - chemically induced
Hypoglycemia - epidemiology
Hypoglycemia - prevention & control
Hypoglycemic Agents - therapeutic use
Insulin
Insulin Glargine
Latin America - epidemiology
suboptimal glycaemic control
Treatment Outcome
type 2 diabetes
Weight Gain
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims This subanalysis of the SoliMix trial assessed the efficacy and safety of advancing basal insulin (BI) therapy with iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D) living in Latin American (LATAM) countries, i.e. Argentina and Mexico (N = 160). Materials and Methods SoliMix (EudraCT: 2017‐003370‐13) was a 26‐week, open‐label, multicentre study, where adults with T2D suboptimally controlled with BI plus one or two oral glucose‐lowering drugs and glycated haemoglobin (HbA1c) ≥7.5% to ≤10% were randomized to once‐daily iGlarLixi or twice‐daily BIAsp 30. Primary efficacy endpoints were non‐inferiority in HbA1c reduction (margin 0.3%) or superiority in body weight change for iGlarLixi versus BIAsp 30. Results Both primary efficacy endpoints were met in the LATAM region. After 26 weeks, HbA1c was reduced by 1.8% with iGlarLixi and 1.4% with BIAsp 30, meeting non‐inferiority [least squares mean difference −0.47% (95% confidence interval: −0.82, −0.11); p 
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.15125